[Comparative efficacy of immunomodulation treatment schemes in patients with herpetic prostatitis].
The immune status was studied in 150 patients with herpetic prostatitis before and after therapy. All the patients were divided into three groups: group 1 (n=50) received standard therapy, group 2 (n=50) received standard therapy plus immunocorrection, group 3 (n=50)--standard therapy, immunocorrection and inductor of interferon. Combined treatment in group 3 produced changes in parameters of cellular and humoral immunity associated with regress of herpetic prostatitis manifestations and reduction in the number of relapses.
Aboian
I A
IA
Tsurikova
E Iu
EIu
D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage; D006558:Herpes Genitalis / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D007167:Immunotherapy; D007372:Interferons / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011472:Prostatitis / Q000150:complications / Q000188:drug therapy*; D012008:Recurrence
D000998:Antiviral Agents; D007155:Immunologic Factors; D007372:Interferons